{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=10&sponsor=Takeda",
    "query": {
      "sponsor": "Takeda",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 1059,
    "total_pages": 106,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=11&sponsor=Takeda&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=9&sponsor=Takeda&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T16:28:12.782Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03859323",
      "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "SHP681",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 104,
      "start_date": "2019-03-26",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03859323"
    },
    {
      "nct_id": "NCT01096680",
      "title": "Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sleep Deprivation"
      ],
      "interventions": [
        {
          "name": "SPD489 20 mg",
          "type": "DRUG"
        },
        {
          "name": "SPD489 50 mg",
          "type": "DRUG"
        },
        {
          "name": "SPD489 70 mg",
          "type": "DRUG"
        },
        {
          "name": "Armodafinil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 135,
      "start_date": "2010-04-05",
      "completion_date": "2010-07-18",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01096680"
    },
    {
      "nct_id": "NCT03997760",
      "title": "A Study of SHP655 (rADAMTS13) in Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "TAK-755",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2019-10-21",
      "completion_date": "2022-10-26",
      "has_results": true,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997760"
    },
    {
      "nct_id": "NCT02760615",
      "title": "Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Colitis, Ulcerative",
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Losartan",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Dextromethorphan",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-11-01",
      "completion_date": "2020-08-01",
      "has_results": false,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 2,
      "location_summary": "Cypress, California • Miami, Florida",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760615"
    },
    {
      "nct_id": "NCT01707667",
      "title": "Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Constipation"
      ],
      "interventions": [
        {
          "name": "prucalopride",
          "type": "DRUG"
        },
        {
          "name": "PEG 3350",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-02-27",
      "completion_date": "2013-11-27",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01707667"
    },
    {
      "nct_id": "NCT06952699",
      "title": "A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Narcolepsy Type 2"
      ],
      "interventions": [
        {
          "name": "TAK-360",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 88,
      "start_date": "2025-05-06",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 31,
      "location_summary": "Auburn, Alabama • Chandler, Arizona • Chula Vista, California + 26 more",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06952699"
    },
    {
      "nct_id": "NCT00671632",
      "title": "Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug Abuse"
      ],
      "interventions": [
        {
          "name": "Ramelteon, triazolam, and placebo (56 possible combinations total)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 14,
      "start_date": "2003-06",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-28",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00671632"
    },
    {
      "nct_id": "NCT00734071",
      "title": "An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Vortioxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 304,
      "start_date": "2008-06",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 33,
      "location_summary": "Anaheim, California • Arcadia, California • Irvine, California + 30 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734071"
    },
    {
      "nct_id": "NCT00798967",
      "title": "Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Short Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "teduglutide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2008-11-25",
      "completion_date": "2011-01-25",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798967"
    },
    {
      "nct_id": "NCT04583007",
      "title": "Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Hereditary Angioedema (HAE)",
        "Angioedema"
      ],
      "interventions": [
        {
          "name": "Lanadelumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Lanadelumab 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-10-19T16:28:12.782Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04583007"
    }
  ]
}